Objective:To determine, during normal pregnancy, maternal serum (MS) and anniotic fluid (AF) concentrations of soluble Fas (sFas), an apoptosis-suppressing molecule that might play a role in the apoptotic process. Soluble Fas levels might explain existing immunotolerance, fetal well being, and rupture of membranes at term.
Methods:Sixty-six healthy, nonsmoking, pregnant women (mean age 32.6 ± 4.8 years) with uncomplicated singleton pregnancies (15 in the first trimester, 30 in the second trimeste, and 21 at term vaginal delivery) and 20 healthy nonpregnant women (mean age 32.5 ± 3.8 years) were included in the study. MS and AF sFas concentrations were measured by a sandwich enzyme-linked immunosorbent assay, and parametric tests were used in the statistical analysis.
Results:MS and AF sFas concentrations significantly depended on gestational age (P < .0008 and P < .0002, respectively). MS concentratiosn were significantly lower in the first trimester than those in the second trimester (P < .003), those at term (P < .03), and those in nonpregnant controls (P < .005). AF concentrations decreased significantly at term compared with those in the second trimester (P < .0003). AF sFas concentrations in the second trimester and at term were significantly lower than respective MS concentrations (P < .00001).
Conclusions:MS sFas concentrations decreased significantly in the first trimester of pregnancy, possibly affecting semiallograft tolerance. In the second trimester, concentrations return to control levels and remain unchanged until delivery. AF sFas concentrations decrease at term compared with the second trimester, possibly indicating increased apoptosis in preparation for rupture of membranes.
1. Reinhard G, Noll A, Schlebusch H, Malimann P, Ruecker AV. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptosis changes. Biochem Biophys Res Commun1998;245:933-938.
2.
2. Nagata S, Golstein P. The Fas death factor. Science1995;267:1449-1456.
3.
3. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science1989;245:301-305.
4.
4. Bellgrau D, Gold D, Selawry H. A role for CD 95 ligand in preventing graft rejection. Nature1995;377:630-632.
5.
5. Griffith T, Brunner T, Fletscher S, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science1995;270:1189-1192.
6.
6. Hoshimoto K, Hayashi M, Ohkura T. Plasma levels of soluble Fas during normal pregnancy. Gynecol Obstet Invest2001;51:96-98.
7.
7. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med1996;2:317-322.
8.
8. Cheng J, Zhou T, Liu C, et al. Orotection of Fas-mediated apoptosis by a soluble form of the Fas molecule. Science1994;263:1759-1762.
9.
9. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by fas/Apo-1 (CD 95) soluble variants prevents cell death in vitro. J Immunol1996;156:4622-4630.
10.
10. Judo S, Kobayashi S, Kayagaki N, et al. Serum levels of soluble Fas/APO-1 (CD 95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol1997;107:89-95.
11.
11. Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum1997;40:80-86.
12.
12. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell1997;88:347-354.
13.
13. Narayanan V. Apoptosis in development and disease of the nervous system. 1. Naturally occurring cell death in the developing nervous system. Pediatr Neurol1997;16:9-13.
14.
14. Lee DM, Osathanondh R, Yeh J. Localization of Bcl-2 in the human fetal mullerian tract. Fertil Steril1998;70:135-140.
15.
15. Brill A, Torchinski A, Carp H, Toder V. The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet1999;16:512-519.
16.
16. Runie R, Lockwood CJ, LaChapelle L, et al. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab1998;83:660-666.
17.
17. Malamitsi-Puchner A, Sarandakou A, Tziotis J, Trikka P, Creatsas G. Evidence for a suppression of apoptosis in early postnatal life. Acta Obstet Gynaecol Scand2001;80:994-997.
18.
18. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T-helper 2-type cytokines at the maternal-fetal interface. J Immunol1993;151:4562-4573.
19.
19. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA1995;273:1933-1936.
20.
20. Clark AG, Kendall MD. The thymus in pregnancy: The interplay of neural, endocrine and immune influences. Immunol Today1994;15:545-551.
21.
21. Medina KL, Smithson G, Kineade PW. Suppression of B lymphopoeisis during normal pregnancy. J Exp Med1993;178:1507-1515.
22.
22. Athanassakis I, Bleackley RC, Paetkau V, Guilbert L, Barr PJ, Wegmann TG. The immunostimulatory effect of T cells and T cell lymphokines on murine fetally derived placental cell. J Immunol1987;138:37-44.
23.
23. Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol1997;177:1395-1401.
24.
24. Moley KH, Chi MM, Knudson CM, Korsmeyer SJ, Mueckler MM. Hyperglycaemia induces apoptosis in pre-implantation embryos through cell death effector pathways. Nat Med1998;4:1421-1424.
25.
25. Forsberg H, Erikson UJ, Welsh N. Apoptosis in embryos of diabetic rats. Pharmacol Toxicol1998;83:104-111.
26.
26. Fortunato SJ, Ramkumar M, Bryant C, Lombardi SJ. Programmed cell death (apoptosis) as a possible pathway to metalloproteinase activation and fetal emmbrane degradation in premature rupture of membranes. Am J Obstet Gynecol2000;182:1468-1476.
27.
27. Seishima M, Takemura M, Saito K, et al. Highly sensitive ELISA for soluble Fas in serum. Increased soluble Fas in the elderly. Clin Chem1996;42:1911-1914.
